PubMed Health⌕ Search

Biomedical subjects

S Halimi

Publications and source records attributed to S Halimi.

At least 19 recordsLinked to original sources

[New treatment strategies for type-2 diabetes?].

Earlier guidelines for type 2 diabetes (Afssaps 1999 and Anaes 2000) were based on the UK Prospective Diabetes Study, published in 1998. These guidelines recommended treatment according to HbA1c value (< 6.5%, between 6.5 and 8% and > 8%): an oral antidiabetic agent for levels > 6.5% despite diet and exercise; combined metformin + sulfonylurea) if HbA1c >8%; and insulin if the latter failed. Blood pressure goals were < 130/80 mmHg, with the antihypertensives necessary to achieve it. The LDL-cholesterol target value was < 1 g/L (for primary prevention in the case of high cardiovascular risk or for secondary prevention) or between 1.3 and 1.6 g/l (primary prevention in the absence of elevated risk). Another reading of the UK study, associated with the arrival of glitazones led to a revision of these objectives with a more aggressive treatment approach ("earlier and stronger"): screen patients for type 2 diabetes earlier, set stricter goals (HbA1c < 6%), and promptly prescribe dual therapy (metformin + sulfonylurea). Should this fail, either glitazone should be added or insulin treatment begun. For most people with type 2 diabetes, the target blood pressure remains 130/80 mmHg, regardless of the type and number of antihypertensive agents necessary. The target drops to 125/75 mmHg for patients with > 300 mg/day microalbuminuria; in these cases, treatment with agents that block the renin-angiotensin system (ACE inhibitors or sartans) is recommended. The LDL cholesterol target value is 1.0 or 1.6 g/L, depending on the cardiovascular risk level. But these guidelines are applied insufficiently, especially in terms of clinical and laboratory follow-up of patients and choice of treatment. All health professionals must participate in the more effective diffusion and application of these guidelines. Patient education is fundamental. The establishment of care networks for these patients seems to us to be the best tool for meeting the objectives of these guidelines.

Administration, Oral↗

[Primary cardiorenal prevention in patients with type-2 diabetes. The Roadmap study].

The incidence of type-2 diabetes is increasing throughout the world. By 2010, 350 million people will have this disease. Microalbuminuria is present in more than one third, for some at diabetes diagnosis. Rather than a complication, it is an indication of a vascular disorder that is part of the metabolic syndrome. 25% will develop end-stage kidney failure. Several studies have identified microalbuminuria or proteinuria as an independent cardiovascular risk factor. Others have shown that antihypertensive treatments acting on the renin-angiotensin system (ACE inhibitors, ARBs agents) can reduce the progression of nephropathy in people with hypertension, type 2 diabetes and microalbuminuria. The "nephroprotective" effects of these drug classes, beyond their role in blood-pressure reduction, are suggested by modifications in renal structure and protein expression. But no study has so far examined their value in primary prevention in persons with type 2 diabetes without--but at risk of developing--microalbuminuria. The Roadmap study (Randomized Olmesartan And Diabetes Microalbuminuria Prevention Study) of primary prevention has as its objective measurement of the impact of ARBs (olmesartan 40 mg/d) treatment on renal outcome in 4400 patients with type 2 diabetes without microalbuminuria. Follow-up of this placebo-controlled study will last for 5 years. Conducted in 200 European centers, its results are expected for 2012.

Adult↗

[The glitazones].

INTRODUCTION: Type 2 diabetes mellitus is one of the biggest public health problem, responsible of major complications. The treatment of hyperglycaemia has been based on lifestyle changes, diet and physical exercise, and oral antidiabetic drugs for reducing the microangiopathic complications and the high cardiovascular risk of these patients. For decades we used sulfonylureas, metformin and alpha glucosidases inhibitors. However these drugs have no effect on muscle insulin resistance, high levels of free fatty acids, lipotoxicity and progressive pancreatic beta-cell loss. EXEGESIS: Thiazolidine-diones or glitazones are the pharmacological ligands of peroxisome proliferator activated receptor gamma mainly expressed in the white adipose tissue. New adipocytes are recruited with, finally, a decrease of free fatty acids, of some cytokines, of muscle and liver insulin resistance. The hypoglycaemic effect is moderate but more pronounced in association with other oral antidiabetic drugs. Long-term studies will possibly confirm the beneficial effects on the beta-cell loss and some cardiovascular parameters in type 2 diabetes and the metabolic syndrome. CONCLUSION: Glitazones enrich the treatment of type 2 diabetes allowing new and synergistic combinations for more precocious and efficient strategies. Moreover their action on peroxisome proliferator activated receptor opens on new therapeutics for cancer, immunology, rheumatology, and infection.

Adipocytes↗

Albumin antioxidant capacity is modified by methylglyoxal.

OBJECTIVE: Oxidative stress seems to play a major role in diabetic vascular complication development. Plasma albumin, via its thiol groups, is the main extracellular antioxidant molecule. Methylglyoxal (MG) is a very reactive dicarbonyl compound increased in diabetes which strongly modifies proteins by non-enzymatic glycosylation. The aim of this work was to study if MG could modify albumin antioxidant capacity. METHODS: Bovine serum albumin was incubated with 1 mM MG at 37 degrees C for 7 days (MG-BSA). Albumin physico-chemical changes were evaluated by tryptophan autofluorescence measurement in the presence or in the absence of a quencher (acrylamide). Albumin antioxidant capacity was determined by thiol measurement using Ellman's reagent as well as in a cellular system (HeLa cells stressed by H2O2). RESULTS: MG-BSA exhibited important modifications as shown by conformational changes, decreased tryptophan autofluorescence (30%) and significant thiol loss (40%). MG-BSA led to important modifications resulting in oxidation and loss of albumin antioxidant capacity. MG-BSA modifications were close to the one observed in albumin isolated from diabetic patients. CONCLUSION: Our results suggest that deleterious effects induced by carbonyl stress in diabetes could also originate from a loss of albumin antioxidant capacity by dicarbonyl compound attack. The biological consequences of these findings have now to be investigated.

Animals↗

[Editorial].

Explore the source record for details and available documents.

Diabetes Mellitus, Type 2↗

[Coming clinical recommendations: where will the glitazones fit in?].

The recommendations for antidiabetic treatment in type 2 diabetes were published by AFSSAPS (Agence Française de Sécurité Sanitaire des Produits de Santé) in 1999. These recommendations, as well as those published by ANAES (Agence Nationale d'Accréditation et d'Evaluation en Santé), indicate an optimal objective for ("good") glycemic control to be an HbA1c level< or =6,5%. These recommendations include two decision trees, according to body mass index (< 28 kg/m2 or >28 kg/m2). Since their publications, our knowledge on diabetes pathophysiology and evolution from insulin resistance to type 2 diabetes, on the progressive decline of pancreatic beta-cell function, and on the close relationships between insulin resistance, type 2 diabetes and cardiovascular diseases, have increased and became more precise. Moreover, new approaches emerged, particularly the importance of the metabolic syndrome and the unfavorable role of visceral fat, when intervention studies (DPP, STOP-NIDDM) demonstrate the possibility to delay and/or to prevent type 2 diabetes. Finally, new oral antidiabetic agents (meteglinides and thiazolidinediones), as well as availability of long-acting insulin analogues, lead to the necessity to update current recommendations. This review, presents and discuss these various points, and the questions they generate, which have to be answer to update the therapeutic recommendations for type 2 diabetes.

Diabetes Mellitus, Type 2↗

[Clinical case: beliefs, Ramadan and diabetes mellitus].

From the clinical case of a 52-Year old, type 2 diabetic obese woman, muslim algerian native, an endocrinologist and a religious representative discuss the influences of religion, beliefs and environment, on compliance to the diabetes diet and therapeutic management, with a particular emphasis on the Ramadan period. Inadequate behaviours, result in a worsening in glucose control. This, should be avoided through an appropriate patient's education, all along the Year, not only through the healthcare team, but involving patient's family and friends too, as well as the community and religious Authorities.

Blood Glucose↗

Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications.

A major aim of glucose-lowering therapy in people with diabetes is to delay or prevent the late-developing complications of diabetes that threaten the quality and duration of life. While intensive interventions to control hyperglycaemia may impair well-being to some extent, the balance of quality of life is usually highly positive. Diet and exercise therapy remains the cornerstone of management, and should usually be given a trial alone first. However, the magnitude and duration of benefit from this intervention is insufficient for most people. More frequent, early, use of metformin is an evidence-based strategy for reducing the risk of adverse outcomes of diabetes in people with type 2 diabetes with sub-optimal glucose control on lifestyle measures alone. This has been recognised in recent evidenced-based guidelines from the UK National Institute for Clinical Excellence and from Diabetes UK, which now support the use of metformin as initial pharmacological therapy for all people without contraindications to the drug. Other national and local guideline committees should consider updating their recommendations on diabetes management in line with these findings.

Body Mass Index↗

Selenium supplementation decreases nuclear factor-kappa B activity in peripheral blood mononuclear cells from type 2 diabetic patients.

OBJECTIVE: The role of selenium in preventing cardiovascular diseases has been largely described. Oxidative stress and the subsequent activation of nuclear factor-kappa B (NF-kappaB) have been linked to the development of vascular complications. We investigated the effects of selenium supplementation in type 2 diabetic patients on several oxidative stress parameters and NF-kappaB activity. METHODS: We enrolled 56 type 2 diabetic patients with similar glycaemic control: 21 were supplemented by selenium (960 micro g d(-1), 3 months) and 27 received a placebo, and 10 nondiabetic subjects formed the control group. To determine NF-kappaB activation, we used an electrophoretic mobility shift assay followed by a semi-quantitative determination of NF-kappaB in peripheral blood mononuclear cells. RESULTS: Selenium treatment resulted in a significant increase in plasma selenium and red-cell Se GSH px activity. It had no effect on lipid peroxidation measured by malone-dialdehyde (MDA) or on red-cell Cu/Zn SOD. NF-kappaB activity was increased by 80% in diabetic patients. In patients receiving selenium supplementation, selenium NF-kappaB activity was significantly reduced, reaching the same level as the nondiabetic control group. CONCLUSION: In type 2 diabetic patients, activation of NF-kappaB measured in peripheral blood monocytes can be reduced by selenium supplementation, confirming its importance in the prevention of cardiovascular diseases.

Diabetes Mellitus, Type 2↗

[Insulin in acute coronary syndromes].

There is a state of major stress during acute coronary syndromes with insulin resistance which results in cardiac cellular metabolism becoming almost completely dependant on fatty acids. This increases cellular oxygen demand with consequent cellular necrosis and apoptosis. Under normal conditions, the metabolism in type 2 diabetes is almost exclusively based on fatty acids. During ischaemia, these phenomena are accentuated which partially explains the higher morbid-mortality after myocardial infarction. It has been demonstrated that insulin administration (GIK) creates conditions for an "optimal milieu" protecting the myocardium during the ischaemic and reperfusion phases by the effects of glucose, the anti-inflammatory action of insulin and its action on NO synthesis. Its efficacy in reduction in post-infarction mortality has been demonstrated in type 2 diabetes in the DIGAMI trial and also in all coronary patients and after cardiac surgery, especially in the ECLA, DUTCH, Texas Heart Institute trials. The results were convergent with respect to insulin dosage, blood sugar levels and volumes of solute, also in the context of cardiac failure. However, in type 2 diabetes, the GIK protocol remains underused in our acute cardiac units and insulin therapy is often prescribed in conditions which do not provide a real benefit. Very few centres use the GIK protocol in non-diabetics in acute coronary syndromes with a risk of loss of benefit for these patients. Therapeutic protocols which can be used by paramedical personnel should be developed.

Acute Disease↗

[Self-monitoring of blood glucose in type 2 diabetic patients. What could we propose according to their treatment?].

Self-monitoring of blood glucose (SMBG) is well acknowledged in type 1 diabetes mellitus (DM). However, although its use is widely recommended in some developed countries, with a significant economical cost, SMBG remains questionable in type 2 DM because its efficacy is not demonstrated by high-quality randomized controlled trials. Type 2 diabetes is an heterogenous disease and its natural history covers several decades. Although type 2 DM represents an important risk of microvascular and cardiovascular complications, it remains asymptomatic for a long time with often a very poor metabolic control and low drug compliance. Treatment of type 2 diabetes varies during these decades, changes in lifestyle at the very beginning, then using oral drugs without risk to develop hypoglycemia (metformin, glitazones, alpha-glucosidases inhibitors) and/or insulin secreting drugs (sulfonylureas or glinides) with potential hypoglycemic risks. At every stage, SMBG could sensitize the patient and possibly could improve glycemias and compliance. SMBG must be adapted to provide informations representing a very useful, motivating and pedagogic tool. Obviously SMBG, in non-insulin-treated type 2 DM, targets other objectives when compared to its use in type 1 DM requiring adapted educational programs to avoid its uselessness and depression of the patient. In insulin treated type 2 DM patients, with a bed time regimen, SMBG represents both a major tool for adjusting the insulin and oral hypoglycemic drugs doses and a comprehensive instrument for controlling and understanding the disease. Thus SMBG is a logical tool for the management of a large proportion of type 2 DM patients but it requires to be proposed in structured counseling educational programs adapted to the psychological and social profile of the patients. These programs must be evaluated by randomized controlled trials.

Administration, Oral↗

[Malignant carotid paraganglioma. A case report].

The most common sites of paragangliomas occurring in the head and neck region are the carotid body and vagal glomus. The clinical course of carotid body paragangliomas is characterized by two modes of development: locoregional growth and distant metastatic dissemination. Few cases of malignant carotid body paraganglioma have been reported in the literature. We report a case managed in the ENT Department of Grenoble university hospital in 1993. A 53-year-old woman presented a bilateral functional (dopamine secretion) carotid tumor, stage II on the right side and stage I on the left side according to the Shamblin classification. Two successive excisions with complete resection were performed without complication. Two years after the second surgical excision, bone and liver metastases were diagnosed and visualized with a Ostreoscan scintigraphy. Clinical course was rapidly unfavorable and the patient died a few weeks later. Malignant forms of carotid paraganglioma are very uncommon and there is no cellular or histological appearance significantly contributing to the diagnosis of malignancy. Clinical findings are the most reliable criteria for malignancy, with the development of distant metastases usually after about 9 years. Long follow-up is essential. Histology in needed to establish the diagnosis of metastasis. A histology specimen may not be possible for a functional paraganglioma. In this case scintigraphy can provide the diagnosis. Malignant forms are more frequent in case of functional paraganglioma, more particularly in case of dopamine secretion.

Carotid Body Tumor↗

[Is a new therapeutic class justified in the treatment of type 2 diabetes?].

Type 2 diabetes is responsible for various micro and macro-vascular complications, appearing early in the course of the disease. The UKPDS results clearly demonstrate the interest of an early and intensive treatment of hyperglycaemia to reduce theses microvascular complications and, to a lesser extent, macrovascular complications. The UKPDS also demonstrate the limits of the current management of type 2 diabetes: delayed diagnosis when several complications already exist, difficulties to maintain an adequate glucose control over the time, particularly with monotherapy, need for an intensive combination treatment policy, unwanted effects of this intensive treatment (weight gain, hypoglycaemias). The 3 classes of oral antidiabetic agents currently available (sulfonylureas and meteglinide analogues, metformin, a-glucosidase inhibitors) imperfectly cover the current therapeutic needs. Thus, the new class, the thiazolidinediones, acting on key physiopathological components, appears as a welcome addition to the treatment of type 2 diabetes. The association of metformin (or a sulfonylurea) and a thiazolidinedione should permit to obtain early a better glycaemic control without the hypoglycaemic risk associated with intensive therapy at an early stage of type 2 diabetes.

Administration, Oral↗

Combination of autoantibody markers and risk for development of type 1 diabetes: results from a large french cohort of family members.

BACKGROUND: The aims of the study were to characterize the relatives at high risk of progression to diabetes and to determine whether rate of progression to diabetes varied according to age, specific combination of antibodies and genetic markers of susceptibility. METHODS: Family members of type 1 diabetic patients were examined through a large medical network for the presence of specific antibodies to beta cell constituents and high risk DQB1 alleles. Antibodies to insulin, GAD and IA-2 as well as ICA were examined in 4,044 family members recruited in a large prospective family study in the Rhone-Alpes region (the GRADI study). Among them, 3,951 non diabetic first degree relatives have been tested on a median of 2.2 occasions and were followed for up to 16 years. RESULTS: Presence of antibodies to GAD (3.6%), IA-2 (4.9%), insulin (2.2%) and ICA at titers equal or above 20JDF units (1.1%) were noticed at the first determination and prevalence increased among ICA positive relatives versus ICA negative relatives. All combinations of markers resulted in specificities above 90%. The positive predictive value of antibodies was dependent on the number of positive antibodies. Combination of antibodies to GAD and IA-2 or GAD and IAA had higher predictive values and sensitivities than ICA titers above 20 JDF units. Additional positivity of IAA increased the predictive value but reduced the sensitivity of the screening procedure. Using a combi GAD/IA-2 assay increased the sensitivity of the screening up to 87.8% but reduced the predictive value to 13.8%. CONCLUSIONS: These data confirm in a large French cohort of first degree relatives of type 1 diabetic patients that combinations of antibodies to beta cell constituents can replace ICA in the first screening procedure. We report that combi GAD/IA-2 assay is well suited for screening purposes. However, time to diabetes in antibody positive relatives appears to be more heterogeneous to what has been described. The importance of genetic markers needs further evaluation.

Autoantibodies↗

2'-deoxyguanosine oxidation is associated with decrease in the DNA-binding activity of the transcription factor Sp1 in liver and kidney from diabetic and insulin-resistant rats.

Over the years, several lines of evidence have emerged supporting the role of oxidative stress in the development of diabetic complications. This could involve the increase in the production of reactive oxygen species and the decrease in antioxidative defense systems. Modulation of the level of intracellular reactive oxygen species is likely to affect the intracellular redox homeostasis, which is crucial for numerous biological events such as the transcriptional activation of genes. In this work we studied the binding of the redox transcription factors Sp1 and NF-kappaB extracted from kidney and liver of streptozotocin diabetic (STZ) and fructose-fed rats using electrophoretic mobility shift (EMSA) assay. In addition, the level in 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodGuo) was assessed within DNA by high performance liquid chromatography with electrochemical detection (HPLC-EC). A decrease in the affinity of Sp1 to DNA was observed in the kidney of STZ rats and fructose-fed rats (15% +/- 8.3 and 54% +/- 6.9, respectively, versus control group set to 100%). This was also found to occur to a lower extent, in the liver. Interestingly, higher levels of 8-oxodGuo, a biomarker of DNA oxidation, were measured in the kidney of diabetic rats. Therefore, the modification in the binding efficiency of Sp1 or NF-kappaB could be related to reactive oxygen species-mediated DNA damage.

8-Hydroxy-2'-Deoxyguanosine↗

Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients.

AIM: To compare the effect of glimepiride in combination with metformin with monotherapy of each drug on glycaemic control in Type 2 diabetic patients. DESIGN AND METHODS: Randomized, double-blind, double-dummy, parallel-group multicentre study conducted in France. Type 2 diabetic patients aged 35-70 years inadequately controlled by metformin monotherapy 2550 mg daily for at least 4 weeks were randomized to either metformin, glimepiride or metformin and glimepiride. RESULTS: Three hundred and seventy-two patients aged 56 +/- 8 years were treated for 5 months. Combination treatment was significantly more efficient in controlling HbA1c (% change + 0.07 +/- 1.20 for metformin, + 0.27 +/- 1.10 for glimepiride, -0.74 +/- 0.96 for combination treatment, P < 0.001), fasting blood glucose (FBG) (mmol/l change + 0.8 +/- 0.4 for metformin, + 0.7 +/- 3.1 for glimepiride and -1.8 +/- 2.2 for combination treatment, P < 0.001) and post-prandial blood glucose (PPBG) (mmol/l change + 1.1 +/- 5.9 for metformin, + 0.1 +/- 5.1 for glimepiride and -2.6 +/- 3.9 for combination treatment, P < 0.001) than either glimepiride or metformin alone. There was no significant difference between metformin or glimepiride monotherapy with respect to the change in HbA1c or FBG; however, glimepiride was significantly more effective than metformin in reducing PPBG. The incidence of symptomatic hypoglycaemia was higher in the combination group than in either monotherapy group (P = 0.039). CONCLUSIONS: Addition of glimepiride to metformin in Type 2 diabetic patients inadequately controlled by metformin alone resulted in superior glycaemic control compared with glimepiride or metformin monotherapy.

Adult↗